Merrimack Pharmaceuticals to Present Clinical Data Across Oncology Pipeline at ASCO 2014
May 22, 2014 17:23 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., May 22, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced it will present clinical data on four novel antibody cancer therapeutics at the 2014...
Merrimack Pharmaceuticals to Present at the Bank of America Merrill Lynch 2014 Health Care Conference
May 07, 2014 16:01 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., May 7, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that Ulrik Nielsen, Chief Scientific Officer, is scheduled to present at the Bank of...
Merrimack Pharmaceuticals Reports First Quarter 2014 Financial Results
May 01, 2014 06:01 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., May 1, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK), a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines...
Merrimack Pharmaceuticals Announces MM-398 Achieves Primary Endpoint of Overall Survival in Phase 3 Trial in Post-Gemcitabine Metastatic Pancreatic Cancer
May 01, 2014 06:00 ET
|
Merrimack Pharmaceuticals
MM-398 in combination with 5-fluorouracil and leucovorin demonstrates statistically significant advantage compared to control arm
Plan to submit New Drug Application in 2014
Conference Call...
Merrimack Announces Preliminary Data From Pilot Diagnostic Imaging Study of MM-398
April 08, 2014 08:00 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., April 8, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced Phase 1 results from a clinical pilot study demonstrating that ferumoxytol*, an iron...
Merrimack to Present at the 2014 American Association for Cancer Research Annual Meeting
March 31, 2014 08:00 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., March 31, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that it will present at the 2014 AACR Annual Meeting. The conference will take place...
Merrimack Provides Fourth Quarter and Full Year 2013 Financial Results
February 27, 2014 16:01 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., Feb. 27, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK), a biopharmaceutical company discovering, developing and preparing to commercialize innovative...
Merrimack to Present at the Cowen and Company 34th Annual Health Care Conference
February 24, 2014 08:00 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., Feb. 24, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that Ulrik Nielsen, Chief Scientific Officer, is scheduled to present at the Cowen and...
Merrimack Announces Timing of Fourth Quarter 2013 Investor Conference Call
February 20, 2014 16:05 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., Feb. 20, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that the company will host its Fourth Quarter 2013 Investor Conference Call and...
Preclinical Study Results of Merrimack's MM-141 Published in Molecular Cancer Therapeutics
February 18, 2014 08:00 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., Feb. 18, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that the manuscript "MM-141, an IGF-1R- and ErbB3-Directed Bispecific Antibody,...